We are pleased to be recommended again in the latest…
![](https://df-mp.com/wp-content/uploads/2018/12/Elisabeth_Greiner.png)
Elisabeth Greiner
Partner
Dr. rer. nat. Mag. pharm.
+ 49 89 210 296 0
elisabeth.greiner@df-mp.com
Elisabeth Greiner
Partner
Dr. rer. nat. Mag. pharm.
+ 49 89 210 296 0
elisabeth.greiner@df-mp.com
![](https://df-mp.com/wp-content/uploads/2018/12/Elisabeth_Greiner.png)
practice areas.
Dr. Greiner's practice focuses on prosecution, opposition and litigation matters concerning German and European patents. With her experience in contentious proceedings, Elisabeth assists her clients with drafting, prosecuting, and assessing patent applications in various fields of life-sciences and chemistry, and has furthermore comprehensive expertise in advising on supplementary protection certificates and coordinating the filing and prosecution of corresponding applications in Germany and throughout Europe.
Elisabeth holds a PhD in pharmaceutical sciences from the University of Innsbruck, Austria, where she also received her doctorate degree for her work in the field of synthetic medicinal chemistry on CNS drugs. Elisabeth honed her in skills as medicinal chemist during her postdoctoral study at the national Institute of Health in Bethesda, MD, USA.
We are delighted to be listed again in this year’s…
df-mp joins the ranks of “highly recommended” patent law firms…
We proudly announce that df-mp is among the most recommended patent…
The pharmaceutical companies Hexal and Teva may continue to sell…
The patent disputes of our client Hexal AG over the…
df-mp is recommended in the current JUVE-Handbook with the highest…
Another leading practitioner in the chemistry and pharmaceutical space is Elisabeth Greiner. Her background lies in organic and medicinal chemistry, and she is a deft hand in formulating defensible, detailed patents in drug discovery and pharmacology.
IAM Patent 1000. 2023
cooperative, friendly and highly experienced in infringement cases
JUVE Handbook, 2019
It is a great pleasure to work with Elisabeth Greiner. Highly experienced in patent litigation, knows all the tricks and trimmings. Highly technically qualified. Perfect work results, very thorough, very careful and very fast.
IAM 500, 2022
The cooperation with Mrs. Elisabeth Greiner is extremely good. She is able to listen very well to understand what is really at stake and is then able to find the appropriate solution. This enables her to provide an excellent service without excessive effort (in time and cost). Her diligence and professionalism are beyond doubt.
IAM 500, 2022
She is outstanding at communicating her technical points to non-technical judges; her pleading style is genuinely impressive. She’s hardworking, dedicated, articulate and creative.
IAM Patent 1000, 2019
Cooperative, considerate, friendly.
IAM Patent 1000, 2019
One of the top pharmaceutical patent practitioners.
IAM Patent 1000, 2019
Convincing in pharmaceutical cases.
JUVE Handbuch 2018
admissions.
- German Patent Attorney
- European Patent Attorney
- European Trademark Attorney
- European Design Attorney
- Unified Patent Court (UPC) representative
EDUCATION
- Pharmacy, University of Innsbruck (Mag. pharm.)
- Doctorate degree in medicinal chemistry, University of Innsbruck, (Dr. rer. nat.)
- Postdoctoral research fellow at the Laboratory of Medicinal Chemistry at the National Institute of Health (NIH) in Bethesda, MD, U.S.A.
AWARDS AND RECOMMENDATIONS.
- Author and co-author of numerous scientific publications in the field of organic and medicinal chemistry
- Organizer of IP-workshops
- Lecturer of IP-seminars at the MCI (Management Center Innsbruck, the entrepreneurial school, Austria)
- Elisabeth has been listed in the IAM patent 1000 as recommended individual („one of the top pharmaceutical patent practitioners“, „outstanding at communicating her technical points to technical judges; her pleading style is genuinely impressive. She is hard-working, dedicated, articulate and creative“), JUVE-Handbook („cooperative, friendly and highly experienced in infringement cases”, “impressive in pharmaceuticals cases”), and also regularly as IP star in the Managing Intellectual Property Magazine.
curriculum vitae.
Representative cases.
- Glatirameracetat / Copaxone®: infringement proceedings, utility model cancellation proceedings
- Fulvestrant / Faslodex®: Formulation patents, nullity proceedings (BGH X ZR 59/17), opposition proceedings, various infringement proceedings
- Fulvestrant / Faslodex®: Patent of use, infringement proceedings
- Calcipotriol – Betamethason / Calcipotriol comp Hexal®: several opposition proceedings, infringement proceedings
- DMF / Tecfidera®: various opposition procedures
- Anti-VEGF Antibody / Avastin® Xeloda®: opposition procedures
association memberships.
publications.
- Greiner, E.; Schottenberger, H.; Wurst, K.; Schmidhammer, H.: Novel Class of Morphinans with Acrylonitrile Incorporated Substructures as Key Intermediates for non-Oxygen-Bridged Opioid Ligands. J. Am. Chem. Soc. 2001, 123, 3840-3841.
- Greiner, E.; Atkinson, A.J.J.; Ayala, A.; Chrousos, G.P.; Contoreggi, C.; Eckelman, W.C.; Gold, P.W.; Habib, K.E.; Jacobson, A.E.; Webster, E.L.; Rice K.C.: Synthesis of Doubly 13C-Labelled Antalarmin Isotopomers for Pharmacokinetic Studies. J. Labelled Cpd. Radiopharm. 2002, 45, 637-645.
- Greiner, E.; Prisinzano, T.; Johnson II, E.M.; Dersch, C.M.; Marcus, J.; Rothman, R.B.; Jacobson, A.E.; Rice, K.C.: Structure-activity relationship studies of highly selective inhibitors of the dopamine transporter: N-benzylpiperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine. J. Med. Chem. 2003, 46, 1465-1469.
- Greiner, E.; Spetea, M.; Krassnig, R.; Schuellner, F.; Aceto, M.; Harris, L.S.; Traynor, J.R.; Woods, J.H.; Winger, G.; Coop, A.; Schmidhammer, H.: Synthesis and Biological Evaluation of 14-Alkoxymorphinans - Part 18 - N-Substituted 14-Phenylpropyloxymorphinan-6-ones with Unanticipated Agonist Properties: Extending the Scope of Common Structure-Activity Relationships. J. Med. Chem. 2003, 46, 1758-1763.
- Jagoda, E.; Contoreggi, C.; Lee, M.; Kao, C.K.; Szajak, L.P.; Listwak, S.; Gold, P.W.; Chrousos, G.P.; Greiner, E.; Kim B.M., Jacobson, A.E.; Rice K.C.: Eckelman, W.: Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: Synthesis of [Br-76]MJL-1-109-2. J. Med. Chem. 2003, 46, 3559-3562.
- Greiner, E.; Folk, J.E.; Jacobson, A.E.; Rice, K.C.: A novel and facile preparation of bremazocine enantiomers through optically pure N-norbremazocines. Bioorg. Med. Chem. 2004, 12, 223-238.
- Seggewiss, R.; Lore, K.; Greiner E.; Magnusson M.K.; Price D.A.; Douek D.C.; Dunbar C.E.; Wiestner A.: Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005, 15, 2473-2479.
- Greiner, E.; Boos, T.L.; Prisinzano T.E.; De Martino, M.G.; Zeglis, B.; Dersch, C.M.; Marcus, J.; Partilla, J.S.; Rothman, R.B.; Jacobson, A.E.; Rice, K.C.: Design and Synthesis of Promiscuous High Affinity Monoamine Transporter Ligands: An Attempt at Unraveling Transporter Selectivity. J. Med. Chem. 2006 Mar 9;49(5):1766-72.
- Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK, Zezula J, Greiner E, Gostick E, Price DA, Einsele H, Seggewiss R. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res. 2008 Apr 15;14(8):2484-91.